Life science biotechnology company pioneering the use of natural psilocybin to treat psychological trauma and various mental illnesses Psyence Group Inc. (CSE: PSYG) revealed having entered into an agreement with a leading psychedelic Contact Research Organization (CRO) named Clerkenwell which is based in the UK.
According to the agreement, both parties will work together to design and deliver palliative care clinical trials in the UK. Palliative care is the treatment and alleviation of suffering for patients suffering from serious acute or persistent medical issues whether the prognosis is deemed chronic or terminal and ongoing.
Recently appointed chief executive officer of Psynce, Dr Neil Maresky, who was very much instrumental in the announcement of this partnership, said both partners will work jointly to ensure this program will become a success.
“As we embark on our journey to commence a clinical trial we are excited to see the promising results from other early-stage clinical trials, which show the efficacy of psychedelic therapies across a multitude of mental health conditions. Clerkenwell’s expertise, depth of knowledge and progressive thinking made them the ideal partner to collaborate with,” said the CEO.
